Combining dasatinib and IFN-α in CML – immunomodulatory effects linked to treatment response and adverse events

ABSTRACT: We pooled 100,000 cells from the 12 scRNA+TCRab-seq samples from peripheral blood from three time points (n=4, samples at 0, 3, and 12 months) to understand the landscape of immune subsets in CML during the course of dasatinib+IFN-α treatment

PROVIDER: EGAS00001005049 | EGA |

REPOSITORIES: EGA